Pharming Group Common Stock Net 2020-2025 | PHAR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pharming Group common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pharming Group common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.3B
Amgen (AMGN)	$162.4B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$92.4B
CSL (CSLLY)	$84B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$61.7B
Alnylam Pharmaceuticals (ALNY)	$55B
Argenex SE (ARGX)	$42.2B
BioNTech SE (BNTX)	$26.5B
Royalty Pharma (RPRX)	$21.3B
Insmed (INSM)	$21.1B
Biogen (BIIB)	$19.4B
Incyte (INCY)	$15.2B
Illumina (ILMN)	$15.1B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.1B
BioMarin Pharmaceutical (BMRN)	$11.6B
Ascendis Pharma (ASND)	$11.3B
QIAGEN (QGEN)	$11.2B
Moderna (MRNA)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$9.9B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.8B
Halozyme Therapeutics (HALO)	$7.4B